All In Biotech

Drug Trial Radar · NCT03881371

A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

Last checked: Nov 19, 2026Latest source record: Mar 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 307 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

307

Actual

Start

Aug 1, 2019

Primary completion

Aug 20, 2021

Study completion Aug 20, 2021

Sponsor

Lead sponsor
Zambon SpAIndustry
Sponsor type
Industry
First posted
Mar 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the effects of 100 mg safinamide, administered orally once daily (OD), in Chinese Parkinson's disease (PD) patients, experiencing motor fluctuations while on stable doses of Levodopa (L-dopa) (alone or in combination with other anti-Parkinson drugs). Eligible patients are required to meet the United Kingdom PD Society Brain Bank Clinical Diagnostic Criteria. The study involves a placebo group. Placebo will be added to the standard stabilized treatment as a control of the safinamide group, hence patients on placebo will have benefit from other ongoing anti-PD medication. A total of 306 patients will be randomised into this study (153 in the safinamide and 153 in the placebo groups).

Conditions

  • Parkinson Disease

Interventions

  • SafinamideDrug

    At baseline (Day 1), eligible patients will be randomised to receive safinamide (initial 50 mg titrated to 100 mg the day after the Visit 3/week 2, ideally at day 15). The investigational medicinal product (IMP) will be taken in the morning at breakfast time, in addition to the morning dose of L-dopa and other (if any) PD medications.

  • PlaceboOther

    At baseline (Day 1), eligible patients will be randomised to receive matching placebo, orally OD. Placebo will be added to the standard stabilized treatment as a control of the safinamide group, hence patients on placebo will have benefit from other ongoing anti-PD medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 16 in the Mean Total Daily "OFF" TimeTime frame: At baseline and Week 16

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Daqing Oilfield General Hospital 大庆油田总医院

    Daqing, China

  • Fujian Medical University Union Hospital 福建医科大学附属协和医院

    Fuzhou, China

  • Qilu Hospital of Shandong University 山东大学齐鲁医院

    Jinan, China

  • Nanjing Drum Tower Hospital 南京鼓楼医院

    Nanjing, China

  • The second affiliated hospital of Soochow University 苏州大学附属第二医院

    Suzhou, China

  • Sir Run Run Shaw Hospital, Zhejiang University 浙江大学医学院附属邵逸夫医院

    Hangzhou, No 3, Qing Chun East Road, China

  • Shanghai Ninth People's Hospital 上海交通大学医学院附属第九人民医院

    Shanghai, No 639, Zhizaoju Road, China

  • Tianjin Union Medicine Center 天津市人民医院

    Tianjin, No. 130, Jie Yuan Rd., Hong Qiao District, China

  • The Third Xiangya Hospital of Central South University 中南大学湘雅三医院

    Changsha, No. 138, Tong Zi Po Road, He XI Yue Lu District, China

  • Renmin Hospital of Wuhan University 武汉大学人民医院

    Wuhan, No. 238, Jie Fang Road, China

  • Sichuan Provincial People's Hospital 四川省医学科学院·四川省人民医院

    Chengdu, No. 32 XI Er Duan, First Ring Road, Qing Yang District, China

  • West China Hospital, Sichuan University 四川大学华西医院

    Chengdu, No. 37, Guoxue Alley, China

  • Beijing Friendship Hospital 首都医科大学附属北京友谊医院

    Beijing, No. 6, Tiantan XI Li, Chongwen District, China

  • Beijing Tiantan Hospital Affiliated to Capital Medical University 首都医科大学附属北京天坛医院

    Beijing, No. 6, Tiantan XI Li, Chongwen District, China

  • The First Bethune Hospital of Jilin University

    Changchun, No. 71, Xin Min Street, China

  • The First Hospital of Shanxi Medical University 山西医科大学第一医院

    Taiyuan, No. 85, Jie Fang South Road, China

  • The Second Affiliated Hospital of Zhejiang University 浙江大学医学院附属第二医院

    Hangzhou, No. 88, Jie Fang Rd., China

  • The Second Affiliated Hospital of Nanchang University 南昌大学第二附属医院

    Nanchang, No.1 Minde Road of Nanchang, China

  • Guangzhou First People's Hospital 广州市第一人民医院

    Guangzhou, No.1 Panfu Rd., China

  • Shanghai General Hospital 上海市第一人民医院

    Shanghai, No.100 Haining Road, China

  • Sun Yat-sen Memorial Hospital 中山大学孙逸仙纪念医院

    Guangzhou, No.107, Yanjiang West Road, China

  • Tongji Hospital of Tongji University 同济大学附属同济医院

    Wuhan, No.1095 Jiefang Avenue, China

  • The Third Hospital of Hebei Medical University 河北医科大学第三医院

    Shijiazhuang, No.139.Zi Qiang Rd, China

  • Chongqing Three Gorges Central Hospital 重庆三峡中心医院

    Chongqing, No.165 Xincheng Rd, Wanzhou District, China

  • Shanghai Ruijin Hospital 上海交通大学医学院附属瑞金医院

    Shanghai, No.197 Ruijin Er Road, China

  • The First Affiliated Hospital of Baotou Medical University 内蒙古科技大学包头医学院第一附属医院

    Baotou, No.41 Linyin Road, China

  • Baotou City Central Hospital 包头市中心医院

    Baotou, No.61, Huancheng Road, Donghe District, China

  • The Affiliated Hospital of Xuzhou Medical University 徐州医科大学附属医院

    Xuzhou, No.99, Huaihai West Road, Xuzhou, Jiangsu, China

  • The Affiliated Hospital Of Guiyang Medical College 贵州医科大学附属医院

    Guiyang, No28. Guiyi Street, China

  • The First Affiliated Hospital of Guangzhou Medical University 广州医科大学附属第一医院

    Guangzhou, Number 151, Yanjiang Road, China

  • Wenzhou Medical College-The First Affiliated Hospital 温州医科大学附属第一医院

    Wenzhou, Shangcai Burg, Ouhai District, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.